7.33
-0.16 (-2.14%)
| Penutupan Terdahulu | 7.49 |
| Buka | 7.41 |
| Jumlah Dagangan | 1,270,322 |
| Purata Dagangan (3B) | 1,961,303 |
| Modal Pasaran | 1,089,106,048 |
| Harga / Jualan (P/S) | 6.05 |
| Harga / Buku (P/B) | 5.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 May 2025 |
| Margin Keuntungan | -74.84% |
| Margin Operasi (TTM) | -56.45% |
| EPS Cair (TTM) | -0.950 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 115.90% |
| Nisbah Semasa (MRQ) | 2.92 |
| Aliran Tunai Operasi (OCF TTM) | -85.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.25 M |
| Pulangan Atas Aset (ROA TTM) | -15.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Adaptive Biotechnologies Corpor | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.34% |
| % Dimiliki oleh Institusi | 91.97% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aristotle Atlantic Partners, Llc | 31 Dec 2024 | 2,886,702 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (Piper Sandler, 77.35%) | Beli |
| Median | 11.00 (50.07%) | |
| Rendah | 9.00 (Morgan Stanley, 22.78%) | Pegang |
| Purata | 11.00 (50.07%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 9.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 06 May 2025 | 13.00 (77.35%) | Beli | 9.84 |
| 20 Feb 2025 | 11.00 (50.07%) | Beli | 8.33 | |
| Morgan Stanley | 05 May 2025 | 9.00 (22.78%) | Pegang | 9.84 |
| Goldman Sachs | 02 May 2025 | 10.00 (36.43%) | Beli | 9.84 |
| 21 Mar 2025 | 9.00 (22.78%) | Beli | 8.40 | |
| Scotiabank | 13 Feb 2025 | 12.00 (63.71%) | Beli | 8.52 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 May 2025 | Pengumuman | Adaptive Biotechnologies Reports First Quarter 2025 Financial Results |
| 10 Apr 2025 | Pengumuman | Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 |
| 08 Apr 2025 | Pengumuman | Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma |
| 11 Mar 2025 | Pengumuman | Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma |
| 11 Feb 2025 | Pengumuman | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |